OverweightPhase 3ATTAIN-NOWNCT07794579
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
A Phase 3 study testing Orforglipron in people with Overweight and Prediabetic State, run by Eli Lilly and Company at 180 sites in 12 countries.
Trial summary
This study will evaluate the efficacy and safety of orforglipron in participants with overweight and assess whether it helps reduce the future risk of obesity-related conditions, including type 2 diabetes, hypertension, and dyslipidemia, and progression to class 1 obesity. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Overweight, Prediabetic State, Prehypertension
- What is being tested?
- Orforglipron
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 2,001 participants
- Where
- 180 sitesin 12 countries
- Study dates
- 26 Aug 2026to Sep 2030
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Have an increased waist-to-height ratio of ≥0.5
- Have at least one pre-obesity-related complication (prediabetes, prehypertension, predyslipidemia)
- Have at least one unsuccessful attempt to reduce body weight based on diet and exercise
- Have a BMI greater than or equal to 25 to less than or equal to 29.9 kg/m2 or equivalent-/region-specific overweight thresholds
Who cannot join
- Have type 1 diabetes, type 2 diabetes, or any other type of diabetes
- Do not have a stable body weight within 90 days before screening
- Have a documented obesity diagnosis or self-reported history of BMI ≥30 kg/m² (or an equivalent region-specific threshold)
- Have taken medications for weight loss, including over-the counter medications or alternative therapies, within 180 days prior to screening
- Have a prior or planned surgical treatment or procedure for obesity
- Have hypertension or history of hypertension
- Have dyslipidemia or history of dyslipidemia
Trial locations and contacts
180 sites in 12 countries. Contact the study team or a site near you to ask about taking part.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or contact
Physicians interested in becoming principal investigators please contact contact
180 sites in 12 countries
United States80 sites, 80 recruiting
- Recruiting
Pinnacle Research Group, LLC
Anniston, Alabama, 36207
256-236-0055
Almena Free
- Recruiting
SKY Clinical Research Network Group-Brown
Atlanta, Georgia, 30331
888-659-4363
Tamara Brown
- Recruiting
IMA Clinical Research Austin
Austin, Texas, 78745
Yu-Mei Liu
- Recruiting
Pennington Biomedical Research Center
Baton Rouge, Louisiana, 70808
225-763-2578
Frank Greenway
- Recruiting
Great Lakes Research Group, Inc.
Bay City, Michigan, 48706
989-895-9100
Jeffrey Potts
- Recruiting
Central Research Associates
Birmingham, Alabama, 35205
205-327-1077
David DeAtkine
- Recruiting
Excel Medical Clinical Trials
Boca Raton, Florida, 33434
305-631-6704
Michael Hafran
- Recruiting
Brigham and Women's Hospital Diabetes Program
Boston, Massachusetts, 02115
617-732-4245
Vanita Aroda
- Recruiting
Headlands Horizons, LLC dba Headlands Research-Brownsville
Brownsville, Texas, 78526
Christopher Romero
- Not yet recruiting
CAMC Institute for Academic Medicine
Charleston, West Virginia, 25304
Harleen Chela
- Recruiting
Great Lakes Clinical Trials - Ravenswood
Chicago, Illinois, 60640
773-275-3500 Ext 162
Rupal Trivedi
- Recruiting
Centennial Medical Group
Columbia, Maryland, 21045
443-698-8678
Rena Johnson
- Recruiting
Remington-Davis, Inc
Columbus, Ohio, 43215
614-487-2560
Roy St. John
- Recruiting
HOPE Clinical Research & Wellness
Conyers, Georgia, 30094
770-679-5591
Alvin Griffin
- Recruiting
The Corvallis Clinic, P.C.
Corvallis, Oregon, 97330
Daniel Barrett
- Recruiting
Cedar Health Research - Texas Native Health
Dallas, Texas, 75235
214-253-8170
Debbie Bridges
- Recruiting
Care Access - Dalton Walmart
Dalton, Georgia, 30720
877-791-0656
Chukwukanene Ofiaeli
- Not yet recruiting
Sovah Clinical Research-River District
Danville, Virginia, 24541
434-793-4711
Stephan Jannach
- Recruiting
Care Access - Decatur
Decatur, Georgia, 30030
678-470-4394
Marie Walton
- Recruiting
Headlands Research-El Paso
El Paso, Texas, 79902
915-910-7088
Ryan Casey
- Recruiting
Cedar Health Research - Euless
Euless, Texas, 76040
214-253-8170
Sefanit Gebretsadik
- Recruiting
Lillestol Research
Fargo, North Dakota, 58104
701-232-7705
Michael Lillestol
- Recruiting
Medication Management
Greensboro, North Carolina, 27401
336-763-6968
James Franklin
- Recruiting
Drug Trials America
Hartsdale, New York, 10530
914-341-2346
Michael Gerdis
- Recruiting
Biopharma Informatic, LLC
Houston, Texas, 77043
281-944-3610
Syed Humayun Naqvi, MD
- Recruiting
Care Access - Houston - Clinical Trials Center by Walmart & Care Access
Houston, Texas, 77082
877-791-0656
Ali Bajwa
- Recruiting
Family First Medical Center
Idaho Falls, Idaho, 83404
208-552-7700
Flint Packer
- Not yet recruiting
Activian Clinical Research
Kingwood, Texas, 77339
832-969-3401
Martin Basaldua
- Recruiting
Frontier Clinical Research, LLC
Kingwood, West Virginia, 26537
304-441-2006
Jeffry Pilney
- Recruiting
New Phase Research and Development
Knoxville, Tennessee, 37909
865-200-8364
Amanda Miller
- Recruiting
Orange County Research Center
Lake Forest, California, 92630
714-550-9990
JOEL NEUTEL
- Recruiting
M3 Wake Research - Las Vegas Cimarron
Las Vegas, Nevada, 89113
702-893-8968
Dana Trippi
- Recruiting
Healthy Brain Clinic
Long Beach, California, 90804
562-606-5999
Dung Trinh
- Not yet recruiting
NYC Research INC
Long Island City, New York, 11106
516-574-9232
Anastasios Manessis
- Recruiting
DCOL Center for Clinical Research
Longview, Texas, 75605
903-238-8854
Kathleen Harris
- Recruiting
Los Angeles Institute for Metabolic Research
Los Angeles, California, 90015
213-373-8380
Juan Frias
- Not yet recruiting
Monroe Biomedical Research - Louisville
Louisville, Kentucky, 40213
502-515-5672
Harold Bays
- Recruiting
Headlands Research-Twin Cities
Maplewood, Minnesota, 55109
Charlene McEvoy
- Recruiting
Care Access - Mauldin
Mauldin, South Carolina, 29662
864-202-6290
Anne Tuggle
- Recruiting
Clinical Renal Associates Ltd.
Media, Pennsylvania, 19063
610-872-8501
Heather Mascio
- Recruiting
Solaris Clinical Research
Meridian, Idaho, 83646
208-288-0123
David Butuk
- Recruiting
Care Access - 801 South Power Road, Mesa
Mesa, Arizona, 85206
877-791-0656
Michael Waters
- Recruiting
Flourish Research Acquisition, LLC dba Flourish Research - North Miami
Miami, Florida, 33138
786-772-0411
Rimsky Denis
- Recruiting
New Age Medical Research Corporation
Miami, Florida, 33186
305-596-9901
Victoria Bedell
- Recruiting
IMA Clinical Research Monroe-Main
Monroe, Louisiana, 71201
318-737-1098
Mark Napoli
- Not yet recruiting
Monroe Biomedical Research
Monroe, North Carolina, 28112
Claire Presswood
- Recruiting
West Clinical Research
Morehead City, North Carolina, 28557
252-515-0050
Patrick Morgante
- Recruiting
Clinical Research Associates Inc
Nashville, Tennessee, 37203
615-329-0197
Stephan Sharp
- Not yet recruiting
Yale University School of Medicine
New Haven, Connecticut, 06519
203-785-7421
Ania Jastreboff
- Recruiting
Renstar Medical Research
Ocala, Florida, 34471
352-629-5800
David Oliver
- Recruiting
Headlands Research Orlando
Orlando, Florida, 32803
407-705-3471
Uzma Khan
- Recruiting
Oviedo Medical Research
Oviedo, Florida, 32765
407-977-2705
Bradley Block
- Recruiting
Desert Oasis Healthcare Medical Group
Palm Springs, California, 92262
760-320-9505
Michael Jardula
- Recruiting
Cahaba Research - Pelham
Pelham, Alabama, 35124
205-408-4134
David Wever
- Not yet recruiting
Absolute Clinical Research
Phoenix, Arizona, 85051
James Beach
- Recruiting
Renascor Clinical Research
Reno, Nevada, 89509
775-544-0376
Sangeeta Wagner
- Recruiting
Clinical Research Partners, LLC
Richmond, Virginia, 23226
804-477-3045
Robert Call
- Recruiting
Artemis Institute for Clinical Research
Riverside, California, 92503
951-374-1190
Jack Vu
- Recruiting
Riverside Clinical
Riverside, California, 92506
951-374-8000
Cydney Osano
- Recruiting
Rochester Clinical Research, LLC
Rochester, New York, 14609
585-288-0890
Patrick Connors
- Recruiting
Headlands Research- Sacramento
Sacramento, California, 95821
916-434-8230
Jeffrey Wayne
- Recruiting
IMA Clinical Research San Antonio
San Antonio, Texas, 78229
210-692-7157
Lisa Blair
- Not yet recruiting
VIP Trials
San Antonio, Texas, 78230
210-569-2672
Juan Garza
- Recruiting
Norcal Endocrinology & Internal Medicine
San Ramon, California, 94583
925-552-5280
Yshay Shlesinger
- Recruiting
Consano Clinical Research, LLC
Shavano Park, Texas, 78231
210-545-4900
Michelle Welch
- Recruiting
Great Lakes Research Institute
Southfield, Michigan, 48075
David Strong
- Recruiting
Clinvest Headlands Llc
Springfield, Missouri, 65807
417-883-7889
Cory Bethmann
- Recruiting
Care Access - St. Petersburg
St. Petersburg, Florida, 33710
877-791-0656
Gigi Lefebvre
- Recruiting
Precision Clinical Research
Sunrise, Florida, 33351
Jeffrey Schneider
- Not yet recruiting
Cotton O'Neil Clinical Research Center
Topeka, Kansas, 66606
785-354-9591
Katherine Willingham
- Not yet recruiting
Arcturus Healthcare , PLC, Troy Internal Medicine Research Division
Troy, Michigan, 48098
248-312-0025
Neil Fraser
- Recruiting
Synexus Clinical Research US, Inc./Orange Grove Family Practice
Tucson, Arizona, 85741
520-333-4515
Kevin Pounds
- Recruiting
Central States Research
Tulsa, Oklahoma, 74136
918-645-5400
Sarah Land
- Recruiting
Care Access - Tyler - Clinical Trials Center by Walmart & Care Access
Tyler, Texas, 75704
877-791-0656
Alphonse Ekole
- Recruiting
Diablo Clinical Research, Inc.
Walnut Creek, California, 94598
925-930-7267
Helen Stacey
- Recruiting
IMA Clinical Research Warren
Warren Township, New Jersey, 07059
Nancy Phillips
- Recruiting
Chase Medical Research, LLC
Waterbury, Connecticut, 06708
203-419-4420
Joseph Soufer
- Recruiting
Suburban Research Associates
West Chester, Pennsylvania, 19380
Omer Abdullah
- Recruiting
Iowa Diabetes and Endocrinology Research Center
West Des Moines, Iowa, 50266
515-329-6800
Anuj Bhargava
- Recruiting
Trial Management Associates - Wilmington - Floral Parkway
Wilmington, North Carolina, 28403
William Jones
Argentina20 sites, 20 recruiting
- Not yet recruiting
CONEXA Investigacion Clinica S.A.
Buenos Aires, 1012
5491169680411
María Scioscia
- Not yet recruiting
CIPREC
Buenos Aires, 1061
5491128690843
Fernando Guerlloy
- Not yet recruiting
CARDIAMET Investigaciones Médicas
Buenos Aires, C1014ACP
5491165496764
Angela Romero Zarante
- Not yet recruiting
Investigaciones Medicas Imoba Srl
Buenos Aires, C1056ABH
541160884234
Silvia Orio
- Not yet recruiting
Centro Médico Viamonte
Buenos Aires, C1120AAC
54 1149635650
Diego Aizenberg
- Not yet recruiting
CEMEDIC
Buenos Aires, C1407GTN
54 11 46356624
Claudio Majul
- Not yet recruiting
Fundación Respirar
Buenos Aires, C1426ABP
5411 7078 1548
Marina Uhrig
- Not yet recruiting
Instituto Centenario
CABA, 1204
5491121559419
SUSANA SALZBERG
- Not yet recruiting
IDIM - Instituto de Investigaciones Metabólicas
Ciudad de Buenos Aires, C1012AAR
5491152266411
Mariela Bazan
- Not yet recruiting
Sanatorio Esperanza
Esperanza, 3080
+ 54 9 3496 655658
Guillermo Cursack
- Not yet recruiting
Centro Diagnóstico Bioimagenes
Lanus, 1824
+5491161529296
DIEGO LOWENSTEIN HABER
- Not yet recruiting
Centro de Investigaciones Médicas Mar del Plata
Mar del Plata, 7600
542234917628
Andres Alvarisqueta
- Not yet recruiting
Instituto de Cardiología Wolff
Mendoza, 5500
5492615636018
SEBASTIAN WOLFF
- Not yet recruiting
Instituto Especialidades de la Salud Rosario
Rosario, 2000
5490341155092114
Ana Chiesa
- Not yet recruiting
Instituto de Investigaciones Clinicas Rosario
Rosario, S2000CVD
5493415109204
Carolina Chacón
- Not yet recruiting
CardioAlem Investigaciones
San Isidro, 1642
+541141844192
Jorge Aiub
- Not yet recruiting
Instituto Médico de Alta Complejidad San Isidro Sa
San Isidro, 1642
01141896249
Maria Montecchiesi
- Not yet recruiting
Centro de Investigaciones Médicas Tucuman
SAN M. de Tucuman, T4000AXL
54-381-4200180
Dina Salica
- Not yet recruiting
Instituto de Investigaciones Clínicas San Nicolas
San Nicolás de los Arroyos, 2900
Maria Fernandez
- Not yet recruiting
Centro de Investigaciones Clinicas del Litoral
Santa Fe, S3000FWO
5403424562779
Miguel Hominal
South Korea12 sites, 12 recruiting
- Not yet recruiting
Korea University Ansan Hospital
Ansan-si, 15355
Ji A Seo
- Not yet recruiting
Hallym University Sacred Heart Hospital
Anyang-si, 14068
Kyung Hee Park
- Not yet recruiting
Pusan National University Yangsan Hospital
Busan, 50612
82-55-360-2860
Sang Yeoup Lee
- Not yet recruiting
Hanyang University Guri Hospital
Guri-si, 11923
Sangmo Hong
- Not yet recruiting
Chosun University Hospital
Gwangju, 61453
Sang Yong Kim
- Not yet recruiting
Kyungpook National University Hospital
Junggu, 41944
Hae-Jin Ko
- Not yet recruiting
Konyang University Hospital
Seogu, 35365
Jee Hyun Kang
- Not yet recruiting
Seoul National University Bundang Hospital
Seongnam, 13620
Kiheon Lee
- Not yet recruiting
CHA Bundang Medical Center, CHA University
Seongnam-si, 13496
Young-Sang Kim
- Not yet recruiting
Korea University Anam Hospital
Seoul, 02841
Sin Gon Kim
- Not yet recruiting
Seoul National University Hospital
Seoul, 03080
82220723497
Minseon Park
- Not yet recruiting
Hanyang University Seoul Hospital
Seoul, 04763
+82-2-2290-8325
Jung Hwan Park
China11 sites, 11 recruiting
- Not yet recruiting
Sichuan Provincial People's Hospital
Chengdu, 610072
Limin Tian
- Not yet recruiting
The Second People's Hospital of Hefei
Hefei, 230011
Yonghong Cao
- Not yet recruiting
The First Affiliated Hospital of Anhui Medical University
Hefei, 230022
Honglin Hu
- Not yet recruiting
Jinan Central Hospital
Jinan, 250013
Nianrong Mi
- Not yet recruiting
The First Affiliated Hospital of Henan University of Science &Technology
Luoyang Shi, 471003
13653880139
Hongwei Jiang
- Not yet recruiting
Nanjing First Hospital
Nanjing, 210006
Qian Li
- Not yet recruiting
Jiangsu Province Official Hospital
Nanjing, 210008
Wei Tang
- Not yet recruiting
The Second Affiliated Hospital of Nanjing Medical University
Nanjing, 210011
18951762960
Yibing Lu
- Not yet recruiting
Ningbo First Hospital
Ningbo, 315010
13757426626
Li Li
- Not yet recruiting
The First Hospital of Qinhuangdao
Qinhuangdao Shi, 066000
15903366689
Bowei Liu
- Not yet recruiting
Tianjin Medical University Zhu Xianyi Memorial Hospital
Tianjin
Liming Chen
Germany10 sites, 10 recruiting
- Not yet recruiting
FutureMeds Berlin
Berlin, 10629
030 3101360
Saskia Kerschischnik
- Not yet recruiting
Siteworks GmbH - Bochum
Bochum, 44787
+49 234 60144350
Annemone Koechel
- Not yet recruiting
Siteworks GmbH - Hannover
Hanover, 30449
Adriana Kandziora
- Not yet recruiting
Dr. MILEK-medikum
Hohenmölsen, 06679
004934441990299
Karsten Milek
- Not yet recruiting
Siteworks - Karlsruhe
Karlsruhe, 76137
004951151524740
Niels-Christian Hoellger
- Not yet recruiting
AmBeNet GmbH
Leipzig, 04107
4934196276326
Hans-Detlev Stahl
- Not yet recruiting
Rahman & Detho Studien GmbH
Obertshausen, 63179
+496104946960
Faisal Detho
- Not yet recruiting
FutureMeds Offenbach
Offenbach, 63065
0049 69 247433849
Christel Contzen
- Not yet recruiting
RED-Institut GmbH
Oldenburg, 23758
0049436150630128
Thomas Schaum
- Not yet recruiting
Sanos Clinic
Ratingen, 40882
021025643873
Jens Harmel
Spain10 sites, 10 recruiting
- Not yet recruiting
Accellacare España
Alcobendas, 28100
34 911148188
Gualberto Diaz
- Not yet recruiting
EAP Sardenya
Barcelona, 08025
935674385
Carlen Reyes Reyes
- Not yet recruiting
Hospital Universitari Vall d'Hebron
Barcelona, 08035
34697817352
ANDREEA CIUDIN
- Not yet recruiting
EAP Osona Sud - Alt Congost S.L.P
Centelles, 08540
Emilia Ruthy Acosta Rojas
- Not yet recruiting
C.R.A. Investigación Clínica
Ferrol, 15402
Alma Maria Prieto tenreiro
- Not yet recruiting
Hospital Vithas La Salud
Granada, 18008
658011529
Cristobal Morales Portillo
- Not yet recruiting
FutureMeds - Madrid
Madrid, 28003
Maria Billon
- Not yet recruiting
Centro de Salud San Juan de la Cruz
Pozuelo de Alarcón, 28224
Alba Pozo Gallego
- Not yet recruiting
Vithas Hospital Sevilla
Seville, 41950
658011529
Cristobal Morales Portillo
- Not yet recruiting
Hospital Ascires
Valencia, 46014
+34 618755407
Emilio Veintimilla
India9 sites, 9 recruiting
- Not yet recruiting
Jawaharlal Nehru Medical College
Aligarh, 202002
Hamid Ashraf
- Not yet recruiting
GMERS Medical College and General Hospital
Baroda, 390021
91 265-2772799
Meenakshi Shah
- Not yet recruiting
Endolife Speciality Hospitals
Guntur, 522001
9849945577
Kongara Srikanth
- Not yet recruiting
Karnataka Institute of Medical Sciences
Hubli, 580021
RAM KAULGUD
- Not yet recruiting
Eternal Heart Care Center and Research Institute
Jaipur, 302020
Jugal Gupta
- Not yet recruiting
Mysore Medical College
Mysore, 570001
7760218464
Sumaiya Anjum
- Not yet recruiting
Datta Meghe Institute of Medical Sciences (DMIMS) - Shalinitai Meghe Hospital and Research Center
Nagpur, 441110
Rajesh Gosavi
- Not yet recruiting
Jothydev's Diabetes and Research Center
Trivandrum, 695032
Jothydev Kesavadev
- Not yet recruiting
Christian Medical College Vellore
Vellore, 632004
Nitin Kapoor
Mexico9 sites, 9 recruiting
- Not yet recruiting
Centro de Estudios de Investigacion Metabolicos y Cardiovasculares, S.C.
Ciudad Madero, 89440
52 1 833 126 00 55
Rafael Violante Ortiz
- Not yet recruiting
Centro Para El Desarrollo de La Medicina Y de Asistencia Medica Especializada S.C.
Culiacán, 80230
6677215355
Manuel de los Rios Ibarra
- Not yet recruiting
Diseno y Planeacion en Investigacion Medica - Guadalajara - Calle Amado Nervo
Guadalajara, 44600
5233305493
Cesar Calvo Vargas
- Not yet recruiting
Kohler & Milstein Research S.A. De C.V.
Mérida, 97070
+529999204004
Jesus Simon Campos
- Not yet recruiting
Medical Care and Research SA de CV
Mérida, 97070
9999203879
Christian González Montaño
- Not yet recruiting
Gastrobariátrica Santa Fe
Mexico City, 05348
Juan Mauricio Vera Zertuche
- Not yet recruiting
Centro de investigación y control metabólico
Monterrey, 66465
81 83488973
Víctor Castelán Vargas
- Not yet recruiting
Servicios Integrales Nova de Monterrey S.A. de C.V.
San Nicolás de los Garza, 66450
Maria Elena Romero-Ibarguengoitia
- Not yet recruiting
Medimanage Research
Tlalpan, 14050
52 5515633053
Nydia Avila-Vanzzini
Czechia7 sites, 7 recruiting
- Not yet recruiting
EFERTUS healthcare s.r.o.
Brno, 615 00
420 606 417 244
Hana Matejovska
- Not yet recruiting
MUDr. Alena Vachova
České Budějovice, 37011
00420720141003
Alena Vachova
- Not yet recruiting
Habrypraktik s.r.o.
Habry, 582 81
420777775579
Sarka Drinkova
- Not yet recruiting
CCR Ostrava s.r.o
Ostrava, 702 00
+420731250539
Jozef Dodulik
- Not yet recruiting
Milan Kvapil s.r.o., Diabetologicka ambulance
Prague, 14900
420272917011
Dagmar Bartaskova
- Not yet recruiting
MUDr. Barbora Diepoltova
Praha 9 - Klanovice, 190 14
420222230131
Barbora Diepoltova
- Not yet recruiting
Medical Plus Research
Uherské Hradiště, 686 01
Eva Dokoupilova
Taiwan5 sites, 5 recruiting
- Not yet recruiting
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, 807
Chun-Ying Lee
- Not yet recruiting
China Medical University Hospital
Taichung, 404332
886923832500
Wen-Yuan Lin
- Not yet recruiting
National Cheng Kung University Hospital
Tainan, 704
886 62353535 ext 3985
Yi-Ching Yang
- Not yet recruiting
National Taiwan University Hospital
Taipei, 10002
Kuo-Chin Huang
- Not yet recruiting
Cathay General Hospital
Taipei, 106
Hai-Hua Chuang
Japan4 sites, 4 recruiting
- Not yet recruiting
Nihonbashi Sakura Clinic
Chūōku, 103-0025
81120023812
Kumie Ito
- Not yet recruiting
Tokyo Asbo Clinic
Chūōku, 104-0031
81120023812
Akiyoshi Uchiyama
- Not yet recruiting
Medical Corporation Heishinkai OCROM Clinic
Suita-shi, 565-0853
81120023812
Yuko Soma
- Not yet recruiting
Tsuchiura Medical & Health Care Center
Tsuchiura, 300-0012
81120023812
Natsuki Imoto
Puerto Rico3 sites, 3 recruiting
- Recruiting
Ponce Medical School Foundation Inc.
Ponce, 00716
1-787-840-2505
Elizabeth Barranco-Santana
- Recruiting
Latin Clinical Trial Center
San Juan, 00909
7879859911
Alex Gonzalez-Bossolo
- Recruiting
Mgcendo Llc
San Juan, 00921
7874842757
Martha Gomez-Cuellar
About this study
Official title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Once-Daily Oral Orforglipron Compared With Placebo in Individuals With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
This study will evaluate the efficacy and safety of orforglipron in participants with overweight and assess whether it helps reduce the future risk of obesity-related conditions, including type 2 diabetes, hypertension, and dyslipidemia, and progression to class 1 obesity.
- Conditions
- Overweight, Prediabetic State, Prehypertension, Obesity, Abdominal
- Being tested
- Orforglipron, Placebo
- Keywords
- Predyslipidemia, Weight management, Cardiovascular risk factors, Obesity prevention, Lower BMI, Early intervention in people with obesity
- Medical subject headings
- Overweight, Prediabetic State, Prehypertension, Obesity, Abdominal
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
OrforglipronDrug
Also called LY3502970
Administered orally
PlaceboDrug
Administered orally
| Study group | Role | What they receive |
|---|---|---|
| Orforglipron | Experimental | Participants will receive orforglipron orally Receives: Drug: Orforglipron |
| Orforglipron to Placebo | Experimental | Participants will receive orforglipron orally followed by placebo orally Receives: Drug: Orforglipron; Drug: Placebo |
| Placebo to Orforglipron | Experimental | Participants will receive placebo orally followed by orforglipron orally Receives: Drug: Orforglipron; Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time to Onset of Obesity Related Complications or Class 1 Obesity
Obesity related complications defined as type 2 diabetes, hypertension, or dyslipidemia; Class 1 obesity defined as body mass index (BMI) ≥30 kilograms per square meter (kg/m2) or an equivalent region-specific threshold
Measured: Baseline to Week 104
Secondary outcomes (12)
Percent Change from Baseline in Body Weight
Measured: Baseline, Week 104
Time to Onset of Waist-to-Height Ratio ≥0.6
Measured: Baseline to Week 104
Change from Baseline in Waist Circumference
Measured: Baseline, Week 104
Time to Onset of Class 1 Obesity
Measured: Baseline to Week 104
Time to First Occurrence of Composite Endpoint of Type 2 Diabetes, Hypertension, Dyslipidemia
Measured: Baseline to Week 104
Time to Onset of Type 2 Diabetes
Measured: Baseline to Week 104
Percent Change from Baseline in Total Fat Mass
Measured: Baseline, Week 104
Change from Baseline in Systolic Blood Pressure
Measured: Baseline, Week 104
Change from Baseline in Glycated Hemoglobin (HbA1c)
Measured: Baseline, Week 104
Percent Change from Baseline in Triglycerides
Measured: Baseline, Week 104
Change from Baseline in Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) Score
Measured: Baseline, Week 104
Pharmacokinetics (PK): Steady-State Area Under the Curve (AUC) of Orforglipron
Measured: Week 4, 12, 24, 52, and 76
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Aug 2026
- Study start26 Aug 2026
- Primary completionAug 2029 (estimated)
- Study completionSep 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for OverweightStudies of the same condition, open and under way.
- More trials run by Eli Lilly and CompanyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 2,001 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Eli Lilly and Company
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Study director, Eli Lilly and Company
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07794579
- Sponsor's protocol ID
- 27823
- Other IDs
- J2A-MC-GZVA, 2026-526175-35-00
- Acronym
- ATTAIN-NOW
- Status last verified
- Oct 2026
- First submitted
- 26 Aug 2026
- Last updated
- 8 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Study at a glance
From the registry record, last updated by the sponsor on 8 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Once-Daily Oral Orforglipron Compared With Placebo in Individuals With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
- ClinicalTrials.gov ID
- NCT07794579
- Acronym / sponsor ID
- ATTAIN-NOW / 27823
- Conditions
- Overweight, Prediabetic State, Prehypertension, Obesity, Abdominal
- Keywords
- Predyslipidemia, Weight management, Cardiovascular risk factors, Obesity prevention, Lower BMI, Early intervention in people with obesity
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 2,001 participants (estimated)
- Lead sponsor
- Eli Lilly and CompanyIndustry (pharma, biotech, devices)
- Study start
- 26 Aug 2026 (actual)
- Primary completion
- Aug 2029 (estimated)
- Study completion
- Sep 2030 (estimated)
- First posted
- 31 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will evaluate the efficacy and safety of orforglipron in participants with overweight and assess whether it helps reduce the future risk of obesity-related conditions, including type 2 diabetes, hypertension, and dyslipidemia, and progression to class 1 obesity.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Orforglipron | Experimental | Drug: OrforglipronParticipants will receive orforglipron orally |
| Orforglipron to Placebo | Experimental | Drug: Orforglipron, Drug: PlaceboParticipants will receive orforglipron orally followed by placebo orally |
| Placebo to Orforglipron | Experimental | Drug: Orforglipron, Drug: PlaceboParticipants will receive placebo orally followed by orforglipron orally |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Have an increased waist-to-height ratio of ≥0.5
- Have at least one pre-obesity-related complication (prediabetes, prehypertension, predyslipidemia)
- Have at least one unsuccessful attempt to reduce body weight based on diet and exercise
- Have a BMI greater than or equal to 25 to less than or equal to 29.9 kg/m2 or equivalent-/region-specific overweight thresholds
Key exclusion criteria (7 listed)
- Have type 1 diabetes, type 2 diabetes, or any other type of diabetes
- Do not have a stable body weight within 90 days before screening
- Have a documented obesity diagnosis or self-reported history of BMI ≥30 kg/m² (or an equivalent region-specific threshold)
- Have taken medications for weight loss, including over-the counter medications or alternative therapies, within 180 days prior to screening
- Have a prior or planned surgical treatment or procedure for obesity
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| OrforglipronAlso: LY3502970Administered orally | Drug | Orforglipron, Orforglipron to Placebo, Placebo to Orforglipron |
| PlaceboAdministered orally | Drug | Orforglipron to Placebo, Placebo to Orforglipron |
Primary outcome
Time to Onset of Obesity Related Complications or Class 1 Obesity
Time frame: Baseline to Week 104
Obesity related complications defined as type 2 diabetes, hypertension, or dyslipidemia; Class 1 obesity defined as body mass index (BMI) ≥30 kilograms per square meter (kg/m2) or an equivalent region-specific threshold
12 secondary outcomes
Percent Change from Baseline in Body Weight
Time frame: Baseline, Week 104
Time to Onset of Waist-to-Height Ratio ≥0.6
Time frame: Baseline to Week 104
Change from Baseline in Waist Circumference
Time frame: Baseline, Week 104
Time to Onset of Class 1 Obesity
Time frame: Baseline to Week 104
Time to First Occurrence of Composite Endpoint of Type 2 Diabetes, Hypertension, Dyslipidemia
Time frame: Baseline to Week 104
Time to Onset of Type 2 Diabetes
Time frame: Baseline to Week 104
Percent Change from Baseline in Total Fat Mass
Time frame: Baseline, Week 104
Change from Baseline in Systolic Blood Pressure
Time frame: Baseline, Week 104
Change from Baseline in Glycated Hemoglobin (HbA1c)
Time frame: Baseline, Week 104
Percent Change from Baseline in Triglycerides
Time frame: Baseline, Week 104
Change from Baseline in Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) Score
Time frame: Baseline, Week 104
Pharmacokinetics (PK): Steady-State Area Under the Curve (AUC) of Orforglipron
Time frame: Week 4, 12, 24, 52, and 76
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Oct 2026.
- A clinical trial for adults looking to maintain their health and reduce their risk of weight-related health conditions (ATTAIN-NOW)Link provided by the sponsor.
- Individual participant dataSharing planned: Yes. Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Related trials for Overweight
RecruitingPhase 4
Translational Health Research Into Vascular and Neurocognitive Effects of Weight Loss
Class I/II Obesity
Not yet recruitingObservational study
Assessing the Impact of Perceptions of Unpredictability on Objective Measures of Food Consumption and Metabolism
Healthy Volunteer, Obestity
RecruitingPhase 1/2
A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity
Overweight and Obesity
Not yet recruitingPhase 4
Effects of Tirzepatide on Esophagogastric Junction Mechanics, Reflux Burden, and Gastric Physiology in Adults With Obesity
Obese Adults
Not yet recruitingObservational study
A Natural History of Genetic and Environmental Predictors of Pubertal Timing Among Youth With Obesity
Obesity
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or contact
Physicians interested in becoming principal investigators please contact contact
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) study director
Eli Lilly and Company
180 sites in 12 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Orforglipron in people with Overweight and Prediabetic State, run by Eli Lilly and Company at 180 sites in 12 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 8 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 180 sites in United States, Argentina, South Korea, China, Germany and 7 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or (317-615-4559, LillyTrials@Lilly.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time to Onset of Obesity Related Complications or Class 1 Obesity (time frame: Baseline to Week 104). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Oct 2026.